SynthesisFrontiers in nutrition2026
The clinical effects of probiotic supplementations on metabolic syndrome: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Probiotics have attracted much attention due to their ability to modulate nutrient metabolism or immunomodulatory. This study aims to evaluate the efficacy of probiotic supplementation in the treatment of metabolic syndrome. Methods: PubMed, Web of Science, Embase, and Cochrane Library were systematically searched searched for eligible clinical trials published from database inception to July 2024. STATA/SE 14.0 software was used for statistical analysis. Results: A total of 12 clinical trials with 633 patients diagnosed with metabolic syndrome were included. The intervention group received probiotic supplementations. The control group received placebo. HDL level was significantly higher with probiotic supplementation than that in the placebo group (WMD = 1.63 mg/dL, 95%CI: [-0.10, 3.36], Conclusion: This study indicates that probiotic supplementation shows potential therapeutic benefit in metabolic syndrome. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42025628477.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.